Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Jun 27, 2018 12:07pm
179 Views
Post# 28237249

RE:RE:RE:When you issue converts...

RE:RE:RE:When you issue converts...I wouldnt describe the discussion as "empty". If just from an emotional/psycological point of view its important to know that these sorts of factors exist in the market and that they can have impacts on various timescales, it's preferrable to being in the dark about what is driving the SP.

The important point for longs is at some point the Trogarzo story will come to dominate the SP again the way it has dominated the turn around in fortunes for the company over the past 2+ years. 



jfm1330 wrote: Sorry, but a lot of empty discussions about why it's down. You don't need to be a very long shareholder to remember a similar shift for no reasons. From mid-January to mid-Februray this year it went from 8.21 $ to 6.86$, a drop of 16.5% in a month and by mid-March it was at 9.95$. Now we have a drop from 14.48 $ to 11.74 $, a drop of 19%. This is pretty similar to me. There is no reasons to explain that other than some are taking profits, like some were taking profits in mid-February before the FDA answer on approval, even though approval was very likely to be given. The same now, some take profits out of fear on Trogarzo sales numbers, but there is no reasons to think they won't be good. This is just normal noise happening with fast growing stocks.




Bullboard Posts